Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | LOX | P28300 | 6/20 | 0.39 |
| ▸ | LOXL2 | Q9Y4K0 | 6/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.34 |
| ▸ | TYK2 | P29597 | 1/20 | 0.34 |
| ▸ | MMP2 | P08253 | 1/20 | 0.34 |
| ▸ | MMP7 | P09237 | 1/20 | 0.34 |
| ▸ | MMP9 | P14780 | 1/20 | 0.34 |
| ▸ | MMP13 | P45452 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | ACACB | O00763 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7125270 | 0.90 | LOXL2 (0.38) | LOXLOXL2SCN9AMMP2MMP7 | |
| SCHEMBL7124884 | 0.87 | POLB (0.39) | KMT2ALOXLOXL2GRM5MMP2 | |
| SCHEMBL7123911 | 0.86 | MAPK14 (0.43) | — | |
| SCHEMBL7126711 | 0.86 | HRH3 (0.47) | KMT2AHRH3SCN9APRKAA2HTT | |
| SCHEMBL7114437 | 0.86 | LOX (0.40) | LOXLOXL2GRM5 | |
| SCHEMBL7124977 | 0.85 | MMP2 (0.41) | KMT2AMMP2MMP7MMP9MMP13 | |
| SCHEMBL7123363 | 0.85 | MMP13 (0.40) | LOXLOXL2GRM5SCN9AMMP2 | |
| SCHEMBL7116456 | 0.84 | EGLN1 (0.39) | GRM5MMP2MMP7MMP9MMP13 | |
| SCHEMBL7124006 | 0.82 | MAPT (0.40) | HRH3GRM5MMP2MMP7MMP9 | |
| SCHEMBL7122473 | 0.82 | EPHX2 (0.39) | LOXLOXL2GRM5SCN9AMMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030069296-A1 | Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-04-10 | — | — | US | claimed |
| US-20030069296-A1 | Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069296-A1 | Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease | CYP7B1, UGT2B7, CYP1B1 | KMT2A 1264/4885LOX 3030/4885LOXL2 4132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.